Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and lowers the price target from $15 to $9.
Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and lowers the price target from $15 to $9.